News | February 10, 2023
Lupin Q2 FY23 revenue up 3.9%; Profit down 71%
With the recent sales force expansion and new product launches, we expect to be back to above-market growth
With the recent sales force expansion and new product launches, we expect to be back to above-market growth
Revenue from operations during the quarter was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal.
The forecast across the seven years between 2022 and 2028 saw an average decline of 7%, resulting in a $10 billion drop in the total forecast sales between 2021 and 2028
For discovery or for standardization, Ayurveda colleges/institutes need to collaborate closely with Phytochemists, Pharmacologists, and Toxicologists from premier institutions
The agreement between Eli Lilly and Janssen was established to allow the two companies to share resources for the goal of accelerating the evaluation of the respective companies’ assets, mirikizumab and Tremfya (guselkumab).
The initiative launched in 2019 has touched over 10,000 lives with 500+ screening camps and aims to double its reach in the next 2 years
It dwells on colocating 157 nursing colleges with medical colleges and eliminating sickle cell anaemia by 2047
DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- and middle-income countries
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
The Durezol brand and generic had US sales of approximately US $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA
Subscribe To Our Newsletter & Stay Updated
